Skip to main content
Log in

STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study

  • Original Paper
  • Published:
Journal of Autism and Developmental Disorders Aims and scope Submit manuscript

Abstract

STX209 (arbaclofen), a selective GABA-B agonist, is hypothesized to modulate the balance of excitatory to inhibitory neurotransmission, and has shown preliminary evidence of benefit in fragile X syndrome. We evaluated its safety, tolerability, and efficacy in non-syndromic autism spectrum disorders, in an 8-week open-label trial enrolling 32 children and adolescents with either Autistic Disorder or Pervasive Developmental Disorder—Not Otherwise Specified, and a score ≥17 on the Aberrant Behavior Checklist (ABC)—Irritability subscale. STX209 was generally well-tolerated. The most common adverse events were agitation and irritability, which typically resolved without dose changes, and were often felt to represent spontaneous variation in underlying symptoms. Improvements were observed on several outcome measures in this exploratory trial, including the ABC-Irritability (the primary endpoint) and the Lethargy/Social Withdrawal subscales, the Social Responsiveness Scale, the CY-BOCS-PDD, and clinical global impression scales. Placebo-controlled study of STX209 is warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Aman, M. G., McDougle, C. J., Scahill, L., Handen, B., Arnold, L. E., Johnson, C., et al. (2009). Medication and parent training in children with pervasive developmental disorders and serious behavior problems: Results from a randomized clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry, 48(12), 1143–1154.

    Article  PubMed  Google Scholar 

  • Baudouin, S. J., Gaudias, J., Gerharz, S., Hatstatt, L., Zhou, K., Punnakkal, P., et al. (2012). Shared synaptic pathophysiology in syndromic and nonsyndromic rodent models of autism. Science, 338(6103), 128–132.

    Article  PubMed  Google Scholar 

  • Bear, M. F., Huber, K. M., & Warren, S. T. (2004). The mGluR theory of fragile X mental retardation. Trends Neuroscience, 27(7), 370–377.

    Article  Google Scholar 

  • Berry-Kravis, E. M., Hessl, D., Rathmell, B., Zarevics, P., Cherubini, M., Walton-Bowen, K., et al. (2012). Effects of STX209 (Arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: A randomized, controlled, phase 2 trial. Science translational medicine, 4(152), 152ra127.

    Google Scholar 

  • Centers for Disease Control. (2012). Prevalence of autism spectrum disorders–autism and developmental disabilities monitoring network, 14 sites, United States, 2008. Morbidity and mortality weekly report. Surveillance summaries, 61(3), 1–19.

    Google Scholar 

  • Fatemi, S. H., Folsom, T. D., Reutiman, T. J., & Thuras, P. D. (2009). Expression of GABA(B) receptors is altered in brains of subjects with autism. Cerebellum, 8(1), 64–69.

    Article  PubMed Central  PubMed  Google Scholar 

  • Gai, X., Xie, H. M., Perin, J. C., Takahashi, N., Murphy, K., Wenocur, A. S., et al. (2012). Rare structural variation of synapse and neurotransmission genes in autism. Molecular Psychiatry, 17(4), 402–411.

    Article  PubMed Central  PubMed  Google Scholar 

  • Gandal, M. J., Edgar, J. C., Ehrlichman, R. S., Mehta, M., Roberts, T. P., & Siegel, S. J. (2010). Validating gamma oscillations and delayed auditory responses as translational biomarkers of autism. Biological Psychiatry, 68(12), 1100–1106.

    Article  PubMed  Google Scholar 

  • Geschwind, D. H. (2009). Advances in autism. Annual Review of Medicine, 60, 367–380.

    Article  PubMed Central  PubMed  Google Scholar 

  • Hagerman, R., Hoem, G., & Hagerman, P. (2010). Fragile X and autism: Intertwined at the molecular level leading to targeted treatments. Mol Autism, 1(1), 12.

    Article  PubMed Central  PubMed  Google Scholar 

  • Henderson, C., Wijetunge, L., Kinoshita, M. N., Shumway, M., Hammond, R. S., Postma, F. R., et al. (2012). Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Science translational medicine, 4(152), 152ra128.

    Google Scholar 

  • Huffman, L. C., Sutcliffe, T. L., Tanner, I. S., & Feldman, H. M. (2011). Management of symptoms in children with autism spectrum disorders: A comprehensive review of pharmacologic and complementary-alternative medicine treatments. Journal of Developmental and Behavioral Pediatrics, 32(1), 56–68.

    Article  PubMed  Google Scholar 

  • Jahromi, L. B., Kasari, C. L., McCracken, J. T., Lee, L. S., Aman, M. G., McDougle, C. J., et al. (2009). Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. Journal of Autism and Developmental Disorders, 39(3), 395–404.

    Article  PubMed  Google Scholar 

  • Kang, Y. H., Sun, B., Park, Y. S., Park, C. S., & Jin, Y. H. (2012). GABA(A) and GABA(B) receptors have opposite effects on synaptic glutamate release on the nucleus tractus solitarii neurons. Neuroscience, 209, 39–46.

    Article  PubMed  Google Scholar 

  • Kelleher, R. J., 3rd, Geigenmuller, U., Hovhannisyan, H., Trautman, E., Pinard, R., Rathmell, B., et al. (2012). High-throughput sequencing of mGluR signaling pathway genes reveals enrichment of rare variants in autism. PLoS One, 7(4), e35003.

    Google Scholar 

  • Krueger, D. D., & Bear, M. F. (2011). Toward fulfilling the promise of molecular medicine in fragile X syndrome. Annual Review of Medicine, 62, 411–429.

    Article  PubMed Central  PubMed  Google Scholar 

  • Kumar, R. A., & Christian, S. L. (2009). Genetics of autism spectrum disorders. Current neurology and neuroscience reports, 9(3), 188–197.

    Article  PubMed  Google Scholar 

  • McPheeters, M. L., Warren, Z., Sathe, N., Bruzek, J. L., Krishnaswami, S., Jerome, R. N., et al. (2011). A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics, 127(5), e1312–e1321.

    Article  PubMed  Google Scholar 

  • Michalon, A., Sidorov, M., Ballard, T. M., Ozmen, L., Spooren, W., Wettstein, J. G., et al. (2012). Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron, 74(1), 49–56.

    Article  PubMed  Google Scholar 

  • Oblak, A. L., Gibbs, T. T., & Blatt, G. J. (2010). Decreased GABA(B) receptors in the cingulate cortex and fusiform gyrus in autism. Journal of Neurochemistry, 114(5), 1414–1423.

    PubMed Central  PubMed  Google Scholar 

  • Paluszkiewicz, S. M., Martin, B. S., & Huntsman, M. M. (2011). Fragile X syndrome: The GABAergic system and circuit dysfunction. Developmental Neuroscience, 33(5), 349–364.

    Article  PubMed Central  PubMed  Google Scholar 

  • Posey, D., Erickson, C., Stigler, K., Diener, J., Kieffer, E., Kohn, A., et al. (2009). A double-blind, placebo-controlled trial of N-acetylcysteine in children with autism spectrum disorders. Paper presented at the American College of Neuropsychopharmacology, 48th annual meeting, Hollywood, FL.

  • Posey, D. J., Erickson, C. A., McDougle, C. J. (2008). Developing drugs for core social and communication impairment in autism. Child and adolescent psychiatric clinics of North America, 17(4), 787–801, viii–ix.

    Google Scholar 

  • Rubenstein, J. L., & Merzenich, M. M. (2003). Model of autism: Increased ratio of excitation/inhibition in key neural systems. Genes Brain Behavior, 2(5), 255–267.

    Article  Google Scholar 

  • Scahill, L., Aman, M. G., McDougle, C. J., McCracken, J. T., Tierney, E., Dziura, J., et al. (2006). A prospective open trial of guanfacine in children with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 16(5), 589–598.

    Article  PubMed  Google Scholar 

  • Scahill, L., Hallett, V., Aman, M. G., McDougle, C. J., Eugene Arnold, L., McCracken, J. T., et al. (2012). Brief report: Social disability in autism spectrum disorder: Results from research units on pediatric psychopharmacology (RUPP) autism network trials. Journal Autism Development Disorder, 43(3), 739–746.

    Google Scholar 

  • Silverman, J. L., Smith, D. G., Rizzo, S. J., Karras, M. N., Turner, S. M., Tolu, S. S., et al. (2012). Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism. Science translational medicine, 4(131), 131ra151.

    Google Scholar 

  • Skafidas, E., Testa, R., Zantomio, D., Chana, G., Everall, I. P., & Pantelis, C. (2012). Predicting the diagnosis of autism spectrum disorder using gene pathway analysis. Molecular Psychiatry. doi:10.1038/mp.2012.126.

  • State, M. W. (2010). The genetics of child psychiatric disorders: Focus on autism and Tourette syndrome. Neuron, 68(2), 254–269.

    Article  PubMed Central  PubMed  Google Scholar 

  • Watson, C., Hoeft, F., Garrett, A. S., Hall, S. S., & Reiss, A. L. (2008). Aberrant brain activation during gaze processing in boys with fragile X syndrome. Archives of General Psychiatry, 65(11), 1315–1323.

    Article  PubMed  Google Scholar 

  • Yizhar, O., Fenno, L. E., Prigge, M., Schneider, F., Davidson, T. J., O’Shea, D. J., et al. (2011). Neocortical excitation/inhibition balance in information processing and social dysfunction. Nature, 477(7363), 171–178.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study was funded by Seaside Therapeutics, Inc. We are grateful to the families who volunteered to participate in this study. Several of the authors are full-time employees of Seaside Therapeutics, Inc., and some hold equity in Seaside Therapeutics, Inc., the sponsor of the study. The remaining authors all served as investigators in the study, and were compensated for their study efforts by Seaside Therapeutics, Inc. Some of these authors also have served as paid consultants to Seaside Therapeutics, Inc.

Conflict of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Paul P. Wang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Erickson, C.A., Veenstra-Vanderweele, J.M., Melmed, R.D. et al. STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study. J Autism Dev Disord 44, 958–964 (2014). https://doi.org/10.1007/s10803-013-1963-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10803-013-1963-z

Keywords

Navigation